

Stockholm, 29 June 2012

Change in number of shares and votes in Swedish Orphan Biovitrum AB

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 29 June 2012 amounts to 267,979,722 shares, of which 265,226,598 common shares and 2,753,124 class C shares*, corresponding to in total 265,501,910.4 votes.

The increase in the number of shares and votes is due to an issue of 684,590 class C shares under the company's long-term incentive programs. The class C shares are intended to ensure fulfillment of commitments under the programs.

For further information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

**All class C shares are held by the company.*

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 29 June 2012 at 08.30 CET.